>

>

Market research for novel oncology drug with NGS vs. IHC diagnostic strategy

Service Areas
Therapeutic Areas

Oncology

Client Type

Mid-size Biotech

Client Problems

  • A mid size biotech company has a drug targeting a rare cancer mutation and wanted to plan an (ideal) CDx test to accompany the drug launch
     

  • They wanted to determine the current usage and future adoption of different molecular diagnostic platforms (single analyte, NGS and liquid biopsy)
     

  • Understand the pro’s and con’s of each platform and determine stakeholders (payers and physicians) perceptions

What We Did

  • Determined treatment flow and molecular diagnostics buy-in process
     

  • Conducted primary market research with stakeholders (oncologists, pathologists, and payers; N=31)
     

  • Secondary market research to analyze the market and competition
     

  • Mapped the niche and adoption of diagnostic platforms (single analyte, NGS, liquid biopsy) in academic vs commercial laboratories

Our Results And Insight

  • Patient flow and diagnostic tests buy-in process
     

  • Determined the drivers and barriers for NGS adoption
     

  • Current use trends and stakeholder opinions of solid NGS, liquid NGS, and IHC

See other case studies

Commercial Strategy case studies >

Market Research case studies >

Oncology case studies >

Service Areas Details

Market Research (Quantitative and Qualitative Study)

Therapeutic Areas Details

Oncology (diagnostics, NGS, Solid Tumor)

© 2019, First Principles Advisory Group. All Rights Reserved
SF Bay Area, Denver, Seattle, New York City, Cambridge
First Principles Advisory Group
1290 Howard Street Suite 323
Burlingame, CA 94010
(415) 669-5183
info@fpadvisory.net